Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk NVO we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $106,450 and 8, calls, for a total amount of $407,096.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $150.0 for Novo Nordisk during the past quarter.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Novo Nordisk stands at 634.4, with a total volume reaching 361.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $90.0 to $150.0, throughout the last 30 days.
Novo Nordisk 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | CALL | TRADE | NEUTRAL | 06/20/25 | $17.75 | $17.4 | $17.56 | $120.00 | $105.3K | 22 | 60 |
| NVO | CALL | SWEEP | NEUTRAL | 12/20/24 | $7.1 | $6.95 | $7.03 | $130.00 | $67.2K | 1.9K | 109 |
| NVO | PUT | TRADE | BULLISH | 11/15/24 | $25.65 | $25.25 | $25.25 | $150.00 | $50.5K | 82 | 20 |
| NVO | CALL | TRADE | BULLISH | 12/20/24 | $9.8 | $9.75 | $9.8 | $125.00 | $49.0K | 404 | 65 |
| NVO | CALL | SWEEP | BULLISH | 01/17/25 | $10.6 | $10.4 | $10.5 | $125.00 | $47.2K | 1.2K | 1 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Novo Nordisk
- Trading volume stands at 1,723,363, with NVO's price up by 1.47%, positioned at $125.52.
- RSI indicators show the stock to be may be approaching oversold.
- Earnings announcement expected in 43 days.
What The Experts Say On Novo Nordisk
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. * An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. * An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
